Skip to Content

'
Boris RA Blechacz, M.D., Ph.D

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Gastroenterology, Hepat,& Nutr, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, SGS, Texas A&M, Health Science Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: Unit #1466
Houston, TX 77030
Phone: 713-794-5073

Education & Training

Degree-Granting Education

2009 Mayo Clinic College of Medicine, Rochester, MN, PHD, Molecular Medicine
1999 University of Heidelberg, Heidelberg, Germany, MD, Magna cum laude, Medicine

Postgraduate Training

2007-2011 Clinical Fellowship, Gastroenterolgoy and Hepatology, Mayo Clinic College of Medicine, Rochester, MN
2005-2007 Clinical Residency, Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN
2002-2005 Research Fellowship, Virology and Gene Therapy, Mayo Clinic College of Medicine, Rochester, MN
1999-2001 Doctor's Medicinae (Doctoral Degree), Virology and Gene Therapy, German Cancer Research Center (DKFZ), Heidelberg, Germany

Professional Memberships

American Association for Cancer Research
Member, 2003-present
American Association for the Study of Liver Diseases
Member, 2008-present
American College of Gastroenterology
Member, 2008-present
American College of Physicians
Member, 2005-present
American Gastroenterological Association
Member, 2003-present
American Medical Association
Member, 2005-present
Bundesaerztekammer (German Physicians’ Association), Germany
Member, 1999-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Blechacz B, Mishra L. Hepatocellular carcinoma biology. Recent Results Cancer Res 190:1-20, 2013. PMID: 22941010.
2. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142(4):1021-1031.e15, 4/2012. e-Pub 12/2011. PMCID: PMC3413201.
3. Thabut D, Routray C, Lomberk G, Shergill U, Glaser K, Huebert R, Patel L, Masyuk T, Blechacz B, Vercnocke A, Ritman E, Ehman R, Urrutia R, Shah V. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 54(2):573-85, 8/2011. e-Pub 6/26/2011. PMCID: PMC3145033.
4. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 8(9):512-22, 2011. e-Pub 8/2/2011. PMID: 21808282.

Book Chapters

1. Blechacz B, Razumilava N, Gores GJ. Annual Screening of PSC patients for cholangiocarcinoma with MRCP and CA19-9 – Yes or no? In: Controversies in Hepatology: The Experts Analyze Both Sides, 1st Edition. In Press.
2. Said AH, Shetty K, Li Y, Blechacz B, Hawk E, Mishra L. Primary Hepatic Cancer. In: Handbook of GastrointestinalCancer, 2012. Ed(s) Jankowski J, Hawk E. In Press.
3. Blechacz B, Gores GJ. Tumors of the Bile Ducts, Gallbladder, and Ampulla. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Ed(s) Feldman L, Friedman LS, Brandt LJ. Saunders. In Press.
4. Breasalier R, Blechacz B. Tumors of the Samll Intestine. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathphysiology, Diagnosis, Management. Ed(s) Feldman L, Friedman LS, Brandt LJ, Blechacz B. Saunders. In Press.
5. Blechacz B, Mishra L. Biology of Hepatocellular Carcinoma. In: Multidisciplinary Treatment of Hepatocellular Carcinoma, 2013. Ed(s) Vauthey JN, Brouquet A. Springer, 2013.
6. Blechacz B, Gores GJ. Genetics and Epidemiology of Cholangiocarcinoma. In: Molecular Genetics of Liver Neoplasia, 1st Edition, 2011.

Last updated: 7/22/2016